Bioiberica presented four research projects at the Osteoarthritis World Congress
The meeting was held on 26-29 April 2018 in Liverpool, UK. A study, made in cooperation with FC Barcelona, found new action mechanisms of chondroitin sulfate and glucosamine. The company also presented updates on the use of biomaterials for cartilage regeneration, the development of predictive patterns for the treatment’ response, and the impact of self-care in osteoarthritis patients.
Bioiberica participated at the Congress of the Osteoarthritis Research Society International (OARSI), presenting significant updates in the clinical and preclinical research of osteoarthritis treatment.
The first of the projects is a preclinical trial, a joint effort by FC Barcelona and Bioiberica that confirms the potential of the combination of chondroitin sulfate and pharma grade glucosamine for the treatment for muscular injuries. This study proved that these drugs play an important role in muscle recovery. More precisely, an increase in muscle cell proliferation, along with the blockade of nuclear translocation NF-kb was observed.
A second preclinical study focuses on cartilage regeneration, by means of hydrogels based on natural polymers. High quality ingredients such as Bioiberica’s hyaluronic acid and chondroitin sulfate were successfully used to synthesize a hydrogel for cartilage repair. This hydrogel has demonstrated excellent adherence and cell proliferation.
Regarding clinical research, one of the updates that were presented at this year’s congress researched the field of response prediction to pharmacological treatment in osteoarthritis patients. Towards that end, scientists carried out a pharma-proteomics essay on serum samples of knee osteoarthritis patients, searching for potential biomarkers that could predict the response to chondroitin sulfate and glucosamine treatment. It was observed that serum levels of a certain protein, when combined with seven clinical and analytical variables, can efficiently predict the response of a given patient to the drug, with 84.3 percent precision.
Finally, Bioiberica presented a new study involving osteoarthritis patients that took part in a training program in self-care and knowledge of that disease. The study was implemented thanks to the collaboration of 60 osteoarthritis patients from the Hospital del Mar and the Primary Care Center of the Olympic Village in Barcelona. The results proved that the training program had a positive impact in regard to pain perception, and improved the patients’ life quality.
All these studies were presented at their respective sessions which took place at hall 2, within the following sessions: cartilage repair, biomarkers, non-pharmacologic therapies and biology of muscle, tendon and ligaments.